DOCSLIB.ORG

0008-5472.CAN-09-2367.Full.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
0008-5472.CAN-09-2367.Full.Pdf Published OnlineFirst October 20, 2009; DOI: 10.1158/0008-5472.CAN-09-2367 Published Online First on October 20, 2009 as 10.1158/0008-5472.CAN-09-2367 Molecular Biology, Pathobiology, and Genetics Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays Elisabetta Caprini,1 Cristina Cristofoletti,1 Diego Arcelli,1 Paolo Fadda,1 Mauro Helmer Citterich,1 Francesca Sampogna,1 Armando Magrelli,2 Federica Censi,2 Paola Torreri,2 Marina Frontani,1 Enrico Scala,1 Maria Cristina Picchio,1 Paola Temperani,3 Alessandro Monopoli,1 Giuseppe Alfonso Lombardo,1 Domenica Taruscio,2 Maria Grazia Narducci,1 and Giandomenico Russo1 1Istituto Dermopatico dell'Immacolata-Istituto di Ricovero e Cura a Carattere Scientifico and 2National Centre for Rare Diseases, Istituto Superiore di Sanità, Rome, Italy; and 3Università di Modena e Reggio Emilia, Unità di Ematologia, Dipartimento di Oncologia ed Ematologia, Modena, Italy Abstract Conventional cytogenetics, allelotyping, and comparative genomic In this study, we used single nucleotide polymorphism and hybridization (CGH) analyses have shown that these tumor cells comparative genomic hybridization array to study DNA copy exhibit chromosomal instability, manifested as allelic gain, loss, number changes and loss of heterozygosity for 28 patients af- or rearrangement (2). Although numerous efforts have been made fected by Sézary syndrome (SS), a rare form of cutaneous T- to clarify how the genomic aberrations might predispose to the cell lymphoma (CTCL). Our data identified, further confirm- development of this disease, the identification of pathogenically ing previous studies, recurrent losses of 17p13.2-p11.2 and relevant genes still remains a challenge. Recently, the application 10p12.1-q26.3 occurring in 71% and 68% of cases, respectively; of high-throughput technologies for genome-wide surveys of genet- common gains were detected for 17p11.2-q25.3 (64%) and ic or expression profiles in CTCL are giving new insights into this – chromosome 8/8q (50%). Moreover, we identified novel ge- malignancy (3 6). Furthermore, there is an increasing tendency to nomic lesions recurring in >30% of tumors: loss of 9q13- integrate mapping and expression data to study the relationship q21.33 and gain of 10p15.3-10p12.2. Individual chromosomal between copy number changes and gene expression levels as a aberrations did not show a significant correlation with significant fraction of genes are altered in a manner consistent prognosis; however, when more than three recurrent chromo- with the underlying genomic alterations in a variety of tumors – somal alterations (gain or loss) were considered, a statistical (7 11) including CTCL (12, 13). The presence of recurrent chromo- association was observed using Kaplan-Meier survival analy- somal copy number alterations (CNA) that correlate with disease sis. Integrating mapping and transcriptional data, we were outcome suggests that changes in the expression of specific genes able to identify a total of 113 deregulated transcripts in aber- within these regions are critical to the disease process (14). rant chromosomal regions that included cancer-related genes Here, we describe a genome-wide analysis, at submegabase res- such as members of the NF-κB pathway (BAG4, BTRC, olution, of DNA copy number changes in 28 SS samples using the NKIRAS2, PSMD3, and TRAF2) that might explain its constitu- single nucleotide polymorphism (SNP) and array CGH (aCGH) tive activation in CTCL. Matching this list of genes with those technology. Our findings identified six regions of highly recurrent discriminating patients with different survival times, we copy number aberrations affecting chromosomes 8, 9, 10, and 17. identify several common candidates that might exert critical Additionally, the SNP technology allowed us to distinguish be- roles in SS, such as BUB3 and PIP5K1B. Altogether, our study tween loss of heterozygosity (LOH) associated with either copy confirms and maps more precisely the regions of gain and number changes, such as hemizygous deletions, or copy number loss and, combined to transcriptional profiles, suggests a neutral status, underlying the involvement of different genetic me- novel set of genes of potential interest in SS. [Cancer Res chanisms that lead to uniparental disomy (UPD) in SS (15). In the 2009;69(21):8438–46] attempt to correlate copy number data and clinical parameters, we find a relationship between complex pattern of chromosomal aber- rations, involving at least three recurrent CNAs, and shorter surviv- Introduction al. We then combined copy number results with gene expression Sézary syndrome (SS) is an aggressive leukemic variant of data from the same SS patients to generate a signature of genes cutaneous T-cell lymphoma (CTCL) that typically presents with differentially expressed and located within the chromosomal erythroderma, peripheral lymphadenopathy, severe pruritus, and regions of interest that include novel potential candidates of SS + malignant circulating CD4 T lymphocytes: the Sézary cells (1). tumor development. Note: Supplementary data for this article are available at Cancer Research Online Materials and Methods (http://cancerres.aacrjournals.org/). Requests for reprints: Giandomenico Russo and Maria Grazia Narducci, Istituto Patients. Peripheral blood samples from 28 SS-affected individuals were Dermopatico dell'Immacolata-Istituto Di Ricovero e Cura a Carattere Scientifico, Via analyzed. All the patients were enrolled in clinical protocols approved by dei Monti di Creta 104, 00167 Rome, Italy. Phone: 39-6-66464798; Fax: 39-6-66462430; the Ethical Committee of the Istituto Dermopatico dell'Immacolata, and E-mail: [email protected] and [email protected]. ©2009 American Association for Cancer Research. informed consent was obtained in accordance with the Declaration of doi:10.1158/0008-5472.CAN-09-2367 Helsinki. Diagnosis of SS was based on described criteria (16). The major Cancer Res 2009; 69: (21). November 1, 2009 8438 www.aacrjournals.org Downloaded from cancerres.aacrjournals.org on September 23, 2021. © 2009 American Association for Cancer Research. Published OnlineFirst October 20, 2009; DOI: 10.1158/0008-5472.CAN-09-2367 SNP and Expression Profiling of Sézary Syndrome Table 1. Highly recurrent CNAs in SS Chr Copy number loss Mb* Genes in SS patients Copy Mb* Genes in SS patiens region† (%) number gain region† (%) Start Stop Size Start Stop Size 8 8p23.3-q24.3 1,13 142,1 140,94 1029 14/28 (50%) 9 9q13-q21.33 69,11 86,66 17,56 115 9/28 (32%) 10 10p12.1-q26.3 25,1 133,8 108,70 1016 19/28 (68%) 10p15.3-10p12.2 0,14 24,02 23,88 187 10/28 (36%) 17 17p13.2-p11.2 3,57 20,15 16,58 388 20/28 (71%) 17p11.2-q25.3 17,35 76,40 59,05 1171 18/28 (64%) *Numerical position based on human genome assembly hg 18 (National Center for Biotechnology Information Build 36.1). † Number of coding transcripts based on genomic sequence information available on Mar 24, 2008 (National Center for Biotechnology Information Build 36.3). clinical and immunologic characteristics, including T-cell receptor clonal hybridization were performed following the Agilent manufacturer's proto- analysis (17) of the samples, are listed in Supplementary Table S1. cols (version 5.0). Images were analyzed using Agilent Feature Extraction Tumor, normal cell isolation, and genomic DNA extraction. Periph- Software version 9.5.1 and data were imported into Agilent CGH analytics eral blood mononuclear cells were separated by Ficoll-Histopaque density software version 3.5 for a graphical overview and analysis. Analysis was per- gradient centrifugation (Sigma-Aldrich). Lymphomonocytes and granulo- formed using the ADM-2 algorithm (Agilent Technologies) with a threshold cytes were separately collected from the gradient fractions. Lymphomono- of 5.3. Experiments showing a derivative log ratio spread value of >0.3 were cytes were subsequently purified by positive selection using anti–human excluded from the analysis. CD3-conjugated dynabeads (Oxoid Ltd.). Granulocytes (normal matched RNA isolation, labeling, and gene expression analysis. Five micro- cells) were obtained collecting the upper phase overlaying the Ficoll density grams of total RNA extracted from sorted T lymphocytes, according to Af- gradient sediment; residual erythrocytes were then lysed by repetitive fymetrix procedure, were reverse transcribed, synthesized in cRNA, washes with a solution of 10 mmol/L Tris-HCl (pH 7.6), 5 mmol/L MgCl2, fragmented, labeled, and hybridized to Human Genome U133A arrays. and 10 mmol/L NaCl. Tumor genomic DNA was isolated from sorted CD3+/ The scanned data were analyzed with a customized script that uses Bio- CD4+ T lymphocytes of SS patients, whereas normal matched DNA was ex- conductor packages6 based on the R language,7 for quality control assess- tracted from the granulocytes of the same individuals according to pub- ment, data normalization, unsupervised and supervised clustering analysis, lished protocols (17). The calculated percentage of tumor cells after and identification of differentially expressed transcripts (19). This R-script purification is indicated for each sample in Supplementary Table S1 and provides utilization of different Bioconductor packages; gcrma package was ranged from 35% to 91%. used for normalization and background correction, and Genefilter package SNP genotyping, LOH, and DNA copy number change. The samples was used to filter genes with highly variance by interquartile range method; were analyzed
Load more

Recommended publications
  • Wo 2010/075007 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075007 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) G06F 19/00 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/12 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/067757 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 11 December 2009 ( 11.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 12/3 16,877 16 December 2008 (16.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): DODDS, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, W., Jean [US/US]; 938 Stanford Street, Santa Monica, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, CA 90403 (US).
    [Show full text]
  • A Minimal Set of Internal Control Genes for Gene Expression Studies in Head
    bioRxiv preprint doi: https://doi.org/10.1101/108381; this version posted February 14, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 A minimal set of internal control genes for gene expression studies in head 2 and neck squamous cell carcinoma. 1 1 1 2 3 Vinayak Palve , Manisha Pareek , Neeraja M Krishnan , Gangotri Siddappa , 2 2 1,3* 4 Amritha Suresh , Moni Abraham Kuriakose and Binay Panda 5 1 6 Ganit Labs, Bio-IT Centre, Institute of Bioinformatics and Applied Biotechnology, 7 Bangalore 560100 2 8 Mazumdar Shaw Cancer Centre and Mazumdar Shaw Centre for Translational 9 Research, Bangalore 560096 3 10 Strand Life Sciences, Bangalore 560024 11 * Corresponding author: [email protected] 12 13 Abstract: 14 Background: Selection of the right reference gene(s) is crucial in the analysis and 15 interpretation of gene expression data. In head and neck cancer, studies evaluating 16 the efficacy of internal reference genes are rare. Here, we present data for a minimal 17 set of candidates as internal control genes for gene expression studies in head and 18 neck cancer. 19 Methods: We analyzed data from multiple sources (in house whole-genome gene 20 expression microarrays, n=21; TCGA RNA-seq, n=42, and published gene 21 expression studies in head and neck tumors from literature) to come up with a set of 22 genes (discovery set) for their stable expression across tumor and normal tissues.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • RT² Profiler PCR Array (96-Well Format and 384-Well [4 X 96] Format)
    RT² Profiler PCR Array (96-Well Format and 384-Well [4 x 96] Format) Human Mitochondria Cat. no. 330231 PAHS-087ZA For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 5700, 7000, 7300, 7500, Format A 7700, 7900HT, ViiA™ 7 (96-well block); Bio-Rad® models iCycler®, iQ™5, MyiQ™, MyiQ2; Bio-Rad/MJ Research Chromo4™; Eppendorf® Mastercycler® ep realplex models 2, 2s, 4, 4s; Stratagene® models Mx3005P®, Mx3000P®; Takara TP-800 RT² Profiler PCR Array, Applied Biosystems models 7500 (Fast block), 7900HT (Fast Format C block), StepOnePlus™, ViiA 7 (Fast block) RT² Profiler PCR Array, Bio-Rad CFX96™; Bio-Rad/MJ Research models DNA Format D Engine Opticon®, DNA Engine Opticon 2; Stratagene Mx4000® RT² Profiler PCR Array, Applied Biosystems models 7900HT (384-well block), ViiA 7 Format E (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (96-well block) Format F RT² Profiler PCR Array, Roche LightCycler 480 (384-well block) Format G RT² Profiler PCR Array, Fluidigm® BioMark™ Format H Sample & Assay Technologies Description The Human Mitochondria RT² Profiler PCR Array profiles the expression of 84 genes involved in the biogenesis and function of the cell's powerhouse organelle. The genes monitored by this array include regulators and mediators of mitochondrial molecular transport of not only the metabolites needed for the electron transport chain and oxidative phosphorylation, but also the ions required for maintaining the mitochondrial membrane polarization and potential important for ATP synthesis. Metabolism and energy production are not the only functions of mitochondria.
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • Nuclear Factor-Erythroid-2 Related Transcription Factor-1 (Nrf1) Is Regulated MARK by O-Glcnac Transferase
    Free Radical Biology and Medicine 110 (2017) 196–205 Contents lists available at ScienceDirect Free Radical Biology and Medicine journal homepage: www.elsevier.com/locate/freeradbiomed Original article Nuclear factor-erythroid-2 related transcription factor-1 (Nrf1) is regulated MARK by O-GlcNAc transferase Jeong Woo Hana,1, Joshua L. Valdeza,1, Daniel V. Hoa, Candy S. Leea, Hyun Min Kima, ⁎ Xiaorong Wangb, Lan Huangb,Jefferson Y. Chana, a Department of Laboratory Medicine and Pathology, University of California, Irvine, D440 Medical Sciences, Irvine, CA 92697, USA b Departments of Physiology and Biophysics, University of California, Irvine, D440 Medical Sciences, Irvine, CA 92697, USA ARTICLE INFO ABSTRACT Keywords: The Nrf1 (Nuclear factor E2-related factor 1) transcription factor performs a critical role in regulating cellular Oxidative stress homeostasis. Using a proteomic approach, we identified Host Cell Factor-1 (HCF1), a co-regulator of tran- O-GlcNAcylation scription, and O-GlcNAc transferase (OGT), the enzyme that mediates protein O-GlcNAcylation, as cellular OGT partners of Nrf1a, an isoform of Nrf1. Nrf1a directly interacts with HCF1 through the HCF1 binding motif Transcription factor (HBM), while interaction with OGT is mediated through HCF1. Overexpression of HCF1 and OGT leads to Protein stability increased Nrf1a protein stability. Addition of O-GlcNAc decreases ubiquitination and degradation of Nrf1a. Transcriptional activation by Nrf1a is increased by OGT overexpression and treatment with PUGNAc. Together, these data suggest that OGT can act as a regulator of Nrf1a. 1. Introduction recognized as an essential co-factor for various transcription factors, and it is involved in regulating a plethora of cellular processes including O-GlcNAc transferase (OGT) is a highly conserved enzyme that cell-cycle progression and gene expression [18–21].
    [Show full text]
  • Supplementary Table S1. Correlation Between the Mutant P53-Interacting Partners and PTTG3P, PTTG1 and PTTG2, Based on Data from Starbase V3.0 Database
    Supplementary Table S1. Correlation between the mutant p53-interacting partners and PTTG3P, PTTG1 and PTTG2, based on data from StarBase v3.0 database. PTTG3P PTTG1 PTTG2 Gene ID Coefficient-R p-value Coefficient-R p-value Coefficient-R p-value NF-YA ENSG00000001167 −0.077 8.59e-2 −0.210 2.09e-6 −0.122 6.23e-3 NF-YB ENSG00000120837 0.176 7.12e-5 0.227 2.82e-7 0.094 3.59e-2 NF-YC ENSG00000066136 0.124 5.45e-3 0.124 5.40e-3 0.051 2.51e-1 Sp1 ENSG00000185591 −0.014 7.50e-1 −0.201 5.82e-6 −0.072 1.07e-1 Ets-1 ENSG00000134954 −0.096 3.14e-2 −0.257 4.83e-9 0.034 4.46e-1 VDR ENSG00000111424 −0.091 4.10e-2 −0.216 1.03e-6 0.014 7.48e-1 SREBP-2 ENSG00000198911 −0.064 1.53e-1 −0.147 9.27e-4 −0.073 1.01e-1 TopBP1 ENSG00000163781 0.067 1.36e-1 0.051 2.57e-1 −0.020 6.57e-1 Pin1 ENSG00000127445 0.250 1.40e-8 0.571 9.56e-45 0.187 2.52e-5 MRE11 ENSG00000020922 0.063 1.56e-1 −0.007 8.81e-1 −0.024 5.93e-1 PML ENSG00000140464 0.072 1.05e-1 0.217 9.36e-7 0.166 1.85e-4 p63 ENSG00000073282 −0.120 7.04e-3 −0.283 1.08e-10 −0.198 7.71e-6 p73 ENSG00000078900 0.104 2.03e-2 0.258 4.67e-9 0.097 3.02e-2 Supplementary Table S2.
    [Show full text]
  • Produktinformation
    Produktinformation Diagnostik & molekulare Diagnostik Laborgeräte & Service Zellkultur & Verbrauchsmaterial Forschungsprodukte & Biochemikalien Weitere Information auf den folgenden Seiten! See the following pages for more information! Lieferung & Zahlungsart Lieferung: frei Haus Bestellung auf Rechnung SZABO-SCANDIC Lieferung: € 10,- HandelsgmbH & Co KG Erstbestellung Vorauskassa Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 Zuschläge F. +43(0)1 489 3961-7 [email protected] • Mindermengenzuschlag www.szabo-scandic.com • Trockeneiszuschlag • Gefahrgutzuschlag linkedin.com/company/szaboscandic • Expressversand facebook.com/szaboscandic PSMD10 Antibody, Biotin conjugated Product Code CSB-PA018899LD01HU Abbreviation 26S proteasome non-ATPase regulatory subunit 10 Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. Uniprot No. O75832 Immunogen Recombinant Human 26S proteasome non-ATPase regulatory subunit 10 protein (1-226AA) Raised In Rabbit Species Reactivity Human Tested Applications ELISA Relevance Acts as a chaperone during the assembly of the 26S proteasome, specifically of the PA700/19S regulatory complex (RC). In the initial step of the base subcomplex assembly is part of an intermediate PSMD10:PSMC4:PSMC5:PAAF1 module which probably assembles with a PSMD5:PSMC2:PSMC1:PSMD2 module. Independently of the proteasome, regulates EGF-induced AKT activation through inhibition of the RHOA/ROCK/PTEN pahway, leading to prolonged AKT activation. Plays an important role in RAS-induced tumorigenesis. Acts as an proto-oncoprotein by being involved in negative regulation of tumor suppressors RB1 and p53/TP53. Overexpression is leading to phosphorylation of RB1 and proteasomal degradation of RB1. Regulates CDK4-mediated phosphorylation of RB1 by competing with CDKN2A for binding with CDK4. Facilitates binding of MDM2 to p53/TP53 and the mono- and polyubiquitination of p53/TP53 by MDM2 suggesting a function in targeting the TP53:MDM2 complex to the 26S proteasome.
    [Show full text]
  • A Novel Resveratrol Analog: Its Cell Cycle Inhibitory, Pro-Apoptotic and Anti-Inflammatory Activities on Human Tumor Cells
    A NOVEL RESVERATROL ANALOG : ITS CELL CYCLE INHIBITORY, PRO-APOPTOTIC AND ANTI-INFLAMMATORY ACTIVITIES ON HUMAN TUMOR CELLS A dissertation submitted to Kent State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy by Boren Lin May 2006 Dissertation written by Boren Lin B.S., Tunghai University, 1996 M.S., Kent State University, 2003 Ph. D., Kent State University, 2006 Approved by Dr. Chun-che Tsai , Chair, Doctoral Dissertation Committee Dr. Bryan R. G. Williams , Co-chair, Doctoral Dissertation Committee Dr. Johnnie W. Baker , Members, Doctoral Dissertation Committee Dr. James L. Blank , Dr. Bansidhar Datta , Dr. Gail C. Fraizer , Accepted by Dr. Robert V. Dorman , Director, School of Biomedical Sciences Dr. John R. Stalvey , Dean, College of Arts and Sciences ii TABLE OF CONTENTS LIST OF FIGURES……………………………………………………………….………v LIST OF TABLES……………………………………………………………………….vii ACKNOWLEDGEMENTS….………………………………………………………….viii I INTRODUCTION….………………………………………………….1 Background and Significance……………………………………………………..1 Specific Aims………………………………………………………………………12 II MATERIALS AND METHODS.…………………………………………….16 Cell Culture and Compounds…….……………….…………………………….….16 MTT Cell Viability Assay………………………………………………………….16 Trypan Blue Exclusive Assay……………………………………………………...18 Flow Cytometry for Cell Cycle Analysis……………..……………....……………19 DNA Fragmentation Assay……………………………………………...…………23 Caspase-3 Activity Assay………………………………...……….….…….………24 Annexin V-FITC Staining Assay…………………………………..…...….………28 NF-kappa B p65 Activity Assay……………………………………..………….…29
    [Show full text]
  • A Cross-Platform Analysis of 14,177 Expression Quantitative Trait Loci Derived from Lymphoblastoid Cell Lines
    Downloaded from genome.cshlp.org on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press Resource A cross-platform analysis of 14,177 expression quantitative trait loci derived from lymphoblastoid cell lines Liming Liang,1 Nilesh Morar,2 Anna L. Dixon,2 G. Mark Lathrop,3 Goncalo R. Abecasis,4 Miriam F. Moffatt,2,5 and William O.C. Cookson2,5,6 1Department of Epidemiology and Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA; 2National Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom; 3Centre National de Genotypage, 91057 Evry Cedex, France; 4Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, Michigan 48109-2029, USA Gene expression levels can be an important link DNA between variation and phenotypic manifestations. Our previous map of global gene expression, based on ~400K single nucleotide polymorphisms (SNPs) and 50K transcripts in 400 sib pairs from the MRCA family panel, has been widely used to interpret the results of genome-wide association studies (GWASs). Here, we more than double the size of our initial data set with expression data on 550 additional individuals from the MRCE family panel using the Illumina whole-genome expression array. We have used new statistical methods for dimension reduction to account for nongenetic effects in estimates of expression levels, and we have also included SNPs imputed from the 1000 Genomes Project. Our methods reduced false-discovery rates and increased the number of ex- pression quantitative trait loci (eQTLs) mapped either locally or at a distance (i.e., in cis or trans) from 1534 in the MRCA data set to 4452 (with <5% FDR).
    [Show full text]
  • Supplementary Table 3: Genes Only Influenced By
    Supplementary Table 3: Genes only influenced by X10 Illumina ID Gene ID Entrez Gene Name Fold change compared to vehicle 1810058M03RIK -1.104 2210008F06RIK 1.090 2310005E10RIK -1.175 2610016F04RIK 1.081 2610029K11RIK 1.130 381484 Gm5150 predicted gene 5150 -1.230 4833425P12RIK -1.127 4933412E12RIK -1.333 6030458P06RIK -1.131 6430550H21RIK 1.073 6530401D06RIK 1.229 9030607L17RIK -1.122 A330043C08RIK 1.113 A330043L12 1.054 A530092L01RIK -1.069 A630054D14 1.072 A630097D09RIK -1.102 AA409316 FAM83H family with sequence similarity 83, member H 1.142 AAAS AAAS achalasia, adrenocortical insufficiency, alacrimia 1.144 ACADL ACADL acyl-CoA dehydrogenase, long chain -1.135 ACOT1 ACOT1 acyl-CoA thioesterase 1 -1.191 ADAMTSL5 ADAMTSL5 ADAMTS-like 5 1.210 AFG3L2 AFG3L2 AFG3 ATPase family gene 3-like 2 (S. cerevisiae) 1.212 AI256775 RFESD Rieske (Fe-S) domain containing 1.134 Lipo1 (includes AI747699 others) lipase, member O2 -1.083 AKAP8L AKAP8L A kinase (PRKA) anchor protein 8-like -1.263 AKR7A5 -1.225 AMBP AMBP alpha-1-microglobulin/bikunin precursor 1.074 ANAPC2 ANAPC2 anaphase promoting complex subunit 2 -1.134 ANKRD1 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 1.314 APOA1 APOA1 apolipoprotein A-I -1.086 ARHGAP26 ARHGAP26 Rho GTPase activating protein 26 -1.083 ARL5A ARL5A ADP-ribosylation factor-like 5A -1.212 ARMC3 ARMC3 armadillo repeat containing 3 -1.077 ARPC5 ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa -1.190 activating transcription factor 4 (tax-responsive enhancer element ATF4 ATF4 B67) 1.481 AU014645 NCBP1 nuclear cap
    [Show full text]
  • Duplication 9P and Their Implication to Phenotype
    Guilherme et al. BMC Medical Genetics (2014) 15:142 DOI 10.1186/s12881-014-0142-1 RESEARCH ARTICLE Open Access Duplication 9p and their implication to phenotype Roberta Santos Guilherme1, Vera Ayres Meloni1, Ana Beatriz Alvarez Perez1, Ana Luiza Pilla1, Marco Antonio Paula de Ramos1, Anelisa Gollo Dantas1, Sylvia Satomi Takeno1, Leslie Domenici Kulikowski2 and Maria Isabel Melaragno1* Abstract Background: Trisomy 9p is one of the most common partial trisomies found in newborns. We report the clinical features and cytogenomic findings in five patients with different chromosome rearrangements resulting in complete 9p duplication, three of them involving 9p centromere alterations. Methods: The rearrangements in the patients were characterized by G-banding, SNP-array and fluorescent in situ hybridization (FISH) with different probes. Results: Two patients presented de novo dicentric chromosomes: der(9;15)t(9;15)(p11.2;p13) and der(9;21)t(9;21) (p13.1;p13.1). One patient presented two concomitant rearranged chromosomes: a der(12)t(9;12)(q21.13;p13.33) and an psu i(9)(p10) which showed FISH centromeric signal smaller than in the normal chromosome 9. Besides the duplication 9p24.3p13.1, array revealed a 7.3 Mb deletion in 9q13q21.13 in this patient. The break in the psu i(9) (p10) probably occurred in the centromere resulting in a smaller centromere and with part of the 9q translocated to the distal 12p with the deletion 9q occurring during this rearrangement. Two patients, brother and sister, present 9p duplication concomitant to 18p deletion due to an inherited der(18)t(9;18)(p11.2;p11.31)mat.
    [Show full text]